{"text_format":"3","workbook":"xlsx","n_sheets":2,"sheets":["Paieška kituose vaisto dokument","Lapas1"],"not_rendered":{"defined_names":1},"read":"whole","date_system":"1900"}

{"sheet":"Paieška kituose vaisto dokument","index":0,"n_rows":13,"n_cols":12,"rows_kept":13}
["VID","Vaisto firminis pavadinimas","Vaisto tarptautinis pavadinimas","Vaisto stiprumas","Vaisto forma","Reg. liud. Nr.","Dokumento rūšis","Dokumento aprašymas","Dokumento pastabos","Dokumento data","Dok. protokolo Nr.","Procedūra"]
[23251,"Capecitabine Zentiva","Kapecitabinas","150mg","plėvele dengtos tabletės","LT/1/12/3145","Raštas","Letter of access",null,"2011-10-03","3R-1.22-16345","DCP"]
[{"$nulls":6},"Registracija",null,"10(1)  \rSE/H/1216/001/DC\nReceptinis, ribotai rašomas","2012-11-19","2012-12-05","DCP"]
[{"$nulls":6},"Raštas",null,"prašymas išbraukti; 2013-07-03 prašymas nebraukti","2013-06-28",null,"DCP"]
[{"$nulls":6},"Pakeitimai","paraiška I tipo 20C-857, protokolas 2013-11-29.   ","RPP papildomi informacija dėl DPD stokos organizme ir kapecitabino vartojimo.\r\nMRP SE/H/1216/001/IB/001 RMS patv. 2013.09.04\r\n","2013-09-04","2013-11-29 (RPP)","DCP"]
[{"$nulls":6},"Pakeitimai","20C-141, protokolas 2014-07-30.     ","PCS ir PL atnaujinami remiantis originatoriaus vaistinio preparato priedais.\r\nUK/H/5684/001/IB/002 RMS patv. 2014.06.19\r\n","2014-06-19","2014-07-30 (PCS,PL)","DCP"]
[{"$nulls":6},"Pakeitimai","20C-2569, protokolas 2015-05-04. ","Pailginamas galutinio produkto tinkamumo laikas. Buvo: 2 metai. Bus 3 metai.\r\nGaliojančioje PCS 6.3 skyriuje keisti galutinio produkto tinkamumo laiką.\r\nUK/H/5684/001-002/IB/004 RMS patv. 2015-05-01\r\n","2015-05-01","2015-05-04 (PCS)","DCP"]
[{"$nulls":6},"Pakeitimai","20C-619","UK/H/5684/001-002/IB/005/G. B.I.a).3. a) Up to 10-fold increase compared to the originally approved batch size \nB.III.2.a). 1 Active substance \nTo add an updated ASMF (version DDL-Capecitabine-AP-006-2014-05-14) for Divis Laboratories Limited.","2015-05-20",null,"DCP"]
[{"$nulls":6},"Pakeitimai","20C-1051, prot. 2015-10-23. ","RPP papildomi informacija susijusi su toksinės leukoencefalopatijos rizika vartojant vaistinį preparatą. RPP atnaujinti pagal naujausią patvirtintą QRD šabloną.\r\nUK/H/5684/001/IB/006\r\n2015.07.24\r\n","2015-07-24","2015-10-23 (RPP)","DCP"]
[{"$nulls":6},"Pakeitimai","20C-1487","UK/H/5684/001-002/IA/016/G. A.1.  Change in the name and/or address of the marketing authorisation holder \n\nChange in the address of the MAH in france from SANOFI AVENTIS FRANCE - 1-13 boulevard Romain Rolland - 75014 PARIS to SANOFI AVENTIS FRANCE - 82 avenue Raspail - 94250 GENTILLY","2015-10-09",null,"DCP"]
[{"$nulls":6},"Pakeitimai","20C-260; prot. 2016-06-20.  ","PCS ir PL papildomi naujausia informacija susijusia DPD trūkumu organizme.\r\nUK/H/5684/001/IB/008 2016.04.01\r\n","2016-04-01","2016-06-20 (PCS,PL)","DCP"]
[{"$nulls":6},"Pakeitimai","20C-1930; prot. 2017-02-24. ","RPP atnaujinami referentinio vaistinio preparato priedais.\r\nUK/H/5684/001-002/IB/009 2016.12.06\r\n","2016-12-06","2017-02-24 (RPP)","DCP"]
[{"$nulls":6},"Pakeitimai",null,"20C-2389;  UK/H/5684/001-002/IA/010. B.III.1.a). 1 New certificate from an already approved manufacturer \nTo register a new EDQM Certificate of Suitability, R0-CEP 2015-111-Rev 01, for the active substance, Capecitabine, manufactured by the approved manufacturer, DIVI'S LABORATORIES LIMITED, Unit 2, Chippada Village, Annavaram Post, Bheemunipatnam Mandal, Visakhapatnam, 531 162, Andhra Pradesh, India, replacing the currently approved ASMF. The CEP supports a conditional re-test period of 2 years.","2016-12-20",null,"DCP"]

{"sheet":"Lapas1","index":1,"n_rows":0,"n_cols":0,"rows_kept":0}